




# THE PEOPLE OF SYNODOS



SYNODOS is a highly integrated, multidisciplinary consortium of scientists, clinicians, and other experts working together to develop treatments for NF2. They come from varying backgrounds – from basic science to translational science, from clinicians to technicians – but all have joined forces to share information and design strategies that will speed up and strengthen the drug discovery process for NF.

**These are the brightest minds in the NF field – please meet the SYNODOS DREAM TEAM LEADERS:**



**Jaishri Blakeley, MD**  
*Associate Professor of  
Neurology, Oncology and  
Neurosurgery at Johns Hopkins  
University*




**James F. Gusella, PhD**  
*Bullard Professor of Neurogenetics,  
Harvard Medical School  
Director, Center for Human  
Genetic Research, Massachusetts  
General Hospital*



**Wade Clapp, MD**  
*Chair of Pediatrics,  
Indiana University School  
of Medicine*



**Scott Plotkin, MD, PhD**  
*Associate Professor  
of Neurology,  
Massachusetts General Hospital*



“SYNODOS IS A SET OF PEOPLE WHO ARE TACKLING A DISEASE IN A WAY THAT IS DRAMATICALLY DIFFERENT FROM THE PAST, AND ALLOWS US TO HAVE INSIGHTS INTO NF THAT WE COULDN'T POSSIBLY HAVE OTHERWISE.”

— **STEPHEN FRIEND, MD, PhD** *President, Co-Founder and Director of Sage Bionetworks*

## CENTERS OF EXCELLENCE

Synodos is a collaboration of researchers from twelve world-class labs at academic and medical centers of excellence, who are for the first time in NF research history sharing datasets in order to develop effective treatments for NF.

### **Jaishri Blakeley, MD**

*Associate Professor of Neurology, Oncology and Neurosurgery at Johns Hopkins University and Director of the Johns Hopkins Comprehensive Neurofibromatosis Center (JHCNC).*

### **Long-Sheng Chang, PhD**

*Investigator in the Center for Childhood Cancer and Blood Diseases, the Research Institute at Nationwide Children's Hospital and Professor in the Department of Pediatrics, The Ohio State University College of Medicine.*

### **Wade Clapp, MD**

*Endowed Professor and Chair of Pediatrics at Indiana University School of Medicine*

### **Cristina Fernandez-Valle, PhD**

*Professor, Burnett School of Biomedical Sciences, University of Central Florida*

### **James Gusella, PhD**

*Bullard Professor of Neurogenetics, Massachusetts General Hospital and Harvard Medical School*

### **Stephen Haggarty, PhD**

*Associate Professor of Neurology, Massachusetts General Hospital and Harvard Medical School*

### **Gary Johnson, PhD**

*Professor and Chair of Pharmacology at the University of North Carolina*

### **Helen Morrison, PhD**

*Molecular biologist and neuroscientist at Fritz-Lipmann-Institute in Jena, Germany*

### **Scott Plotkin, MD, PhD**

*Associate Professor of Neurology, Massachusetts General Hospital and Harvard Medical School.*

### **Vijaya Ramesh, PhD**

*Associate Professor of Neurology, Massachusetts General Hospital and Harvard Medical School.*

### **Anat Stemmer-Rachamimov, MD**

*Associate Professor in Pathology, Massachusetts General Hospital and Harvard Medical School*

### **D. Bradley Welling, MD, PhD**

*Chief of Otolaryngology, Massachusetts General Hospital, Chairman of Otolaryngology and Laryngology, Harvard Medical School*

## EXTERNAL ADVISORS

### **Stephen Friend, MD, PhD**

*President, Co-Founder and Director of Sage Bionetworks*  
Dr. Friend is on this committee because of his track record in community building.

### **Bruce R. Korf, MD, PhD**

*Chair, Department of Genetics and Director, Heflin Center for Genomic Sciences at the University of Alabama at Birmingham*  
Dr. Korf is on this committee because of his established recognition in NF.

### **Gordon B. Mills, MD, PhD**

*Chair of Gynecology and Chair of Systems Biology in the Division of Cancer Medicine, and co-head of the Kleberg Center for Molecular Markers at the University of Texas*  
Dr. Mills is on this committee because of his track record as a dream team leader for Stand Up To Cancer.

### **Terry Van Dyke, PhD**

*Head of the Mouse Cancer Genetics Program at the National Cancer Institute*

Dr. Van Dyke is on this committee because of her track record in Tg animal models and preclinical testing.

### **Tracy Tulloh Galloway**

*Synodos Founding Supporter, Children's Tumor Foundation Board Member, NF2 Patient Representative*




“THE UNIQUE VALUE OF THIS CONSORTIUM IS IN ITS COLLABORATIVE AND MULTIDISCIPLINARY ACTIVITY, BRINGING RESEARCHERS TOGETHER IN A WAY SO AS TO UNDERSTAND NF2 IN ALL ITS CHARACTERISTICS AND MANIFESTATIONS.”

— **ANNETTE BAKKER, PHD**

*President and Chief Scientific Officer of the Children's Tumor Foundation*

FOR MORE INFORMATION: [ctf.org/synodos](http://ctf.org/synodos)



120 Wall Street, 16th Floor  
New York, NY 10005 | 212-344-6633 | [www.ctf.org](http://www.ctf.org)

